Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...